83 FR 60878 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 228 (November 27, 2018)

Page Range		60878-60879
FR Document		2018-25789

Federal Register, Volume 83 Issue 228 (Tuesday, November 27, 2018)

[Federal Register Volume 83, Number 228 (Tuesday, November 27, 2018)]
[Notices]
[Pages 60878-60879]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-25789]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; Centers for AIDS Research and 
Developmental Centers for AIDS Research (P30).
    Date: December 11-12, 2018.
    Time: 9:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel & Conference Center, 5701 
Marinelli Road, Bethesda, MD 20852.
    Contact Person: Audrey O. Lau, Ph.D., MPH, Acting Senior 
Scientific Review Officer, AIDS Review Branch, SRP, Rm. 3E70, 
National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9834, 
Rockville, MD 20852-9834, 240-669-2081, [email protected].

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID Investigator Initiated 
Program Project Applications (P01).
    Date: December 19, 2018.
    Time: 12:30 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Frank S. De Silva, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, Room #3E72A, National Institutes of Health/NIAID, 5601 
Fishers Lane, MSC 9823, Rockville, MD 20892-9823, (240) 669-5023, 
[email protected].

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID Investigator Initiated 
Program Project Applications (P01).
    Date: December 20, 2018.
    Time: 9:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.

[[Page 60879]]

    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Frank S. De Silva, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, Room #3E72A, National Institutes of Health/NIAID, 5601 
Fishers Lane, MSC 9823, Rockville, MD 20892-9823, (240) 669-5023, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: November 20, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-25789 Filed 11-26-18; 8:45 am]
 BILLING CODE 4140-01-P

60878 Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices

Child Care and Indian Child Care regular contact with, or control over, the age of 18 to assure that all existing
Worker Positions (OMB No. 0917–0028). Indian children. 25 U.S.C. 3207(a)(1) and newly hired employees undergo a
Type of Information Collection Request: and (2). Title 25 U.S.C. 3207(a)(3) criminal history background check. The
Extension, without revision, of currently requires regulations prescribing the background investigation is to be
approved information collection, 0917– minimum standards of character for initiated through the personnel program
0028, Addendum to Declaration for individuals appointed to positions of the applicable Federal agency. This
Federal Employment, Child Care and involving regular contact with, or section requires employment
Indian Child Care Worker Positions. control over, Indian children, and applications for individuals who are
There are no program changes or section 3207(b) provides that such seeking work for an agency of the
adjustments in burden hours. Form(s): standards shall ensure that no such Federal Government, or for a facility or
Addendum to Declaration for Federal individuals have been found guilty of, program operated by (or through
Employment, Child Care and Indian or entered a plea of nolo contendere or contract with) the Federal Government,
Child Care Worker Positions. Need and guilty to any felonious offense, or any in positions involved with the provision
Use of Information Collection: This is a two or more misdemeanor offenses, of child care services to children under
request for approval of the collection of under Federal, State, or Tribal law the age of 18, to contain a question
information as required by section 408 involving crimes of violence; sexual asking whether the individual has ever
of the Indian Child Protection and assault, molestation, exploitation, been arrested for or charged with a
Family Violence Prevention Act, Public contact or prostitution; crimes against crime involving a child, and if so,
Law (Pub. L.) 101–630, 104 Stat. 4544, persons; or offenses committed against requiring a description of the
and 25 United States Code (U.S.C.) children. disposition of the arrest or charge.
§§ 3201–3210. In addition, 34 U.S.C. 20351 (formerly
The IHS is required to compile a list codified at 42 U.S.C. 13041, which was Affected Public: Individuals and
of all authorized positions within the transferred to 34 U.S.C. 20351) requires households. Type of Respondents:
IHS where the duties and each agency of the Federal Government, Individuals.
responsibilities involve regular contact and every facility operated by the The table below provides: Types of
with, or control over, Indian children; Federal Government (or operated under data collection instruments, Estimated
and to conduct an investigation of the contract with the Federal Government), number of respondents, Number of
character of each individual who is that hires (or contracts for hire) responses per respondent, Average
employed, or is being considered for individuals involved with the provision burden hour per response, and Total
employment, in a position having of child care services to children under annual burden hour(s).

ESTIMATED ANNUAL BURDEN HOURS
Average Total annual
Number of
Number of burden per burden
Data collection instrument(s) responses per
respondents response responses
respondent (in hours) (in hours)

Addendum to Declaration for Federal Employment (OMB 0917–0028) ......... 3,000 1 12/60 600

Total .......................................................................................................... 3,000 ........................ ........................ 600

There are no Capital Costs, Operating provisions set forth in sections 20852–9834, 240–669–2081, audrey.lau@
Costs, and/or Maintenance Costs to 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., nih.gov.
report. as amended. The grant applications and Name of Committee: National Institute of
Dated: November 19, 2018. the discussions could disclose Allergy and Infectious Diseases Special
confidential trade secrets or commercial Emphasis Panel; NIAID Investigator Initiated
Michael D. Weahkee, Program Project Applications (P01).
property such as patentable material,
Assistant Surgeon General, U.S. Public Health Date: December 19, 2018.
Service, Principal Deputy Director, Indian
and personal information concerning
individuals associated with the grant Time: 12:30 p.m. to 4:30 p.m.
Health Service. Agenda: To review and evaluate grant
[FR Doc. 2018–25819 Filed 11–26–18; 8:45 am]
applications, the disclosure of which
applications.
would constitute a clearly unwarranted
BILLING CODE 4165–16–P Place: National Institutes of Health, 5601
invasion of personal privacy. Fishers Lane, Rockville, MD 20892
Name of Committee: National Institute of (Telephone Conference Call).
DEPARTMENT OF HEALTH AND Allergy and Infectious Diseases Special Contact Person: Frank S. De Silva, Ph.D.,
HUMAN SERVICES Emphasis Panel; Centers for AIDS Research Scientific Review Officer, Scientific Review
and Developmental Centers for AIDS Program, Division of Extramural Activities,
National Institutes of Health Research (P30). Room #3E72A, National Institutes of Health/
Date: December 11–12, 2018. NIAID, 5601 Fishers Lane, MSC 9823,
National Institute of Allergy and Time: 9:00 a.m. to 6:00 p.m. Rockville, MD 20892–9823, (240) 669–5023,
Infectious Diseases; Notice of Closed Agenda: To review and evaluate grant
fdesilva@niaid.nih.gov.
applications.
Meetings
amozie on DSK3GDR082PROD with NOTICES1

Place: Bethesda North Marriott Hotel & Name of Committee: National Institute of
Conference Center, 5701 Marinelli Road, Allergy and Infectious Diseases Special
Pursuant to section 10(d) of the Emphasis Panel; NIAID Investigator Initiated
Bethesda, MD 20852.
Federal Advisory Committee Act, as Contact Person: Audrey O. Lau, Ph.D., Program Project Applications (P01).
amended, notice is hereby given of the MPH, Acting Senior Scientific Review Date: December 20, 2018.
following meetings. Officer, AIDS Review Branch, SRP, Rm. Time: 9:00 a.m. to 1:00 p.m.
The meetings will be closed to the 3E70, National Institutes of Health, NIAID, Agenda: To review and evaluate grant
public in accordance with the 5601 Fishers Lane, MSC 9834, Rockville, MD applications.

VerDate Sep<11>2014 17:45 Nov 26, 2018 Jkt 247001 PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\27NON1.SGM 27NON1

Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices 60879

Place: National Institutes of Health, 5601 with the Acquired Immunodeficiency • Increase in melting temperature (10
Fishers Lane, Rockville, MD 20892 Syndrome (AIDS) pandemic. degrees over BG505 SOSIP).
(Telephone Conference Call). One approach researchers have taken Development Stage: In vivo testing
Contact Person: Frank S. De Silva, Ph.D., to elicit broadly neutralizing antibodies (rodents).
Scientific Review Officer, Scientific Review
against HIV–1 is to stabilize the Inventors: Peter Kwong (NIAID), John
Program, Division of Extramural Activities,
Room #3E72A, National Institutes of Health/ structurally flexible HIV–1 envelope Mascola (NIAID), Gwo-Yu Chuang
NIAID, 5601 Fishers Lane, MSC 9823, (Env) trimer. Researchers stabilized the (NIAID), Cheng Cheng (NIAID), Hui
Rockville, MD 20892–9823, (240) 669–5023, Env trimer in a conformation that Geng (NIAID), Yongping Yang (NIAID)
fdesilva@niaid.nih.gov. displays predominantly broadly and Jeffrey C. Boyington (NIAID).
(Catalogue of Federal Domestic Assistance neutralizing epitopes and few non- Intellectual Property: HHS Reference
Program Nos. 93.855, Allergy, Immunology, neutralizing epitopes. Currently, BG505 Number E–240–2017 includes U.S.
and Transplantation Research; 93.856, DS–SOSIP is a leading vaccine Provisional Patent Application Number
Microbiology and Infectious Diseases candidate with the desired 62/579,973 filed 10/16/2017.
Research, National Institutes of Health, HHS) Related Intellectual Property: HHS
conformation and antigenicity.
Dated: November 20, 2018. Ideally, to be useful as a vaccine, such Reference Number E–187–2014 includes
Natasha M. Copeland, a conformationally fixed Env U.S. Provisional Patent Application
Program Analyst, Office of Federal Advisory immunogen should have high Number 62/046,059 filed 9/4/2014, U.S.
Committee Policy. thermostability and should remain in Provisional Patent Application Number
[FR Doc. 2018–25789 Filed 11–26–18; 8:45 am] the desired antigenic state, even in the 62/136,480 filed 3/21/2015, PCT
BILLING CODE 4140–01–P presence of CD4, a glycoprotein found Application No. PCT/US2015/048729
on the surface of immune cells. filed 9/4/2015, US Patent Application
Researchers at the Vaccine Research 15/508,885 filed 3/3/2017, EP Patent
DEPARTMENT OF HEALTH AND Center (VRC) of the National Institute of Application Number 15766697.5 filed
HUMAN SERVICES Allergy and Infectious Diseases (NIAID) 3/29/2017.
undertook efforts to improve the Licensing Contact: Barry Buchbinder,
National Institutes of Health properties of BG505 DS–SOSIP for use Ph.D., 240–627–3678;
as a vaccine. The VRC researchers barry.buchbinder@nih.gov.
Government-Owned Inventions; introduced three additional mutations Dated: November 14, 2018.
Availability for Licensing to further stabilize BG505 DS–SOSIP in Suzanne M. Frisbie,
AGENCY: National Institutes of Health, the vaccine-preferred prefusion-closed Deputy Director, Technology Transfer and
HHS. conformation and refer to the Intellectual Property Office, National Institute
ACTION: Notice. engineered BG505 DS–SOSIP as BG505 of Allergy and Infectious Diseases.
DS–SOSIP.3mut. Experiments showed [FR Doc. 2018–25787 Filed 11–26–18; 8:45 am]
SUMMARY: The invention listed below is that these modifications conferred BILLING CODE 4140–01–P
owned by an agency of the U.S. improved thermostability that will
Government and is available for allow easier transport and storage of
licensing to achieve expeditious BG505 DS–SOSIP.3mut compared to DEPARTMENT OF HEALTH AND
commercialization of results of BG505 DS–SOSIP. In addition, BG505 HUMAN SERVICES
federally-funded research and DS–SOSIP.3mut has lower antigenicity
development. Foreign patent toward non/weak neutralizing National Institutes of Health
applications are filed on selected antibodies compared to BG505 DS–
inventions to extend market coverage SOSIP, which suggests that it could National Cancer Institute; Notice of
for companies and may also be available potentially elicit higher neutralization Closed Meetings
for licensing. titer by targeting only broadly Pursuant to section 10(d) of the
FOR FURTHER INFORMATION CONTACT: neutralizing antibodies. With improved Federal Advisory Committee Act, as
Barry Buchbinder, Ph.D., 240–627– antigenicity and stability, this version amended, notice is hereby given of the
3678; barry.buchbinder@nih.gov. may have utility as an HIV–1 following meetings.
Licensing information and copies of the immunogen or in other antigen-specific The meetings will be closed to the
U.S. patent application listed below contexts, such as for use with B-cell public in accordance with the
may be obtained by communicating probes. provisions set forth in sections
with the indicated licensing contact at This technology is available for 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
the Technology Transfer and licensing for commercial development as amended. The grant applications and
Intellectual Property Office, National in accordance with 35 U.S.C. 209 and 37 the discussions could disclose
Institute of Allergy and Infectious CFR part 404. confidential trade secrets or commercial
Diseases, 5601 Fishers Lane, Rockville, Potential Commercial Applications property such as patentable material,
MD 20852; tel. 301–496–2644. A signed and personal information concerning
Confidential Disclosure Agreement will • Vaccine—to elicit potent individuals associated with grant
be required to receive copies of neutralizing antibodies against the HIV– applications, the disclosure of which
unpublished patent applications. 1 Env glycoprotein. would constitute a clearly unwarranted
SUPPLEMENTARY INFORMATION:
• Probes—to identify broad and invasion of personal privacy.
Technology description follows. potent HIV–1-neutralizing antibodies.
Name of Committee: National Cancer
amozie on DSK3GDR082PROD with NOTICES1

Recombinant HIV–1 Envelope Proteins Competitive Advantages Institute Special Emphasis Panel; NCI SPORE
I (P50) Review.
and Their Use Compared to previous engineered Env Date: January 29–30, 2019.
trimer versions: Time: 8:00 a.m. to 12:00 p.m.
Description of Technology • 300-fold reduction in CD4-binding Agenda: To review and evaluate grant
An effective human affinity. applications.
immunodeficiency virus type 1 (HIV–1) • Reduced binding affinity to Place: Hilton Washington/Rockville Hotel,
vaccine has long been sought to contend ineffective HIV–1 antibodies. 1750 Rockville Pike, Rockville, MD 20850.

VerDate Sep<11>2014 17:45 Nov 26, 2018 Jkt 247001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 E:\FR\FM\27NON1.SGM 27NON1

Document Created: 2018-11-27 01:24:09
Document Modified: 2018-11-27 01:24:09

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		December 11-12, 2018.
FR Citation		83 FR 60878

83 FR 60878 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 228 (November 27, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health